Evotec surges on €30M BVF investment; J&J files for approval of rare blood disorder drug; Ex-Dendreon CEO launches biotech hedge fund;

@FierceBiotech: ICYMI: Merck triggers patent war with Gilead over sofosbuvir rights. Story | Follow @FierceBiotech

@JohnCFierce: Schoenbaum's take on Amgen's demand for unblinded Kyprolis trial data: Poker move by Bradway to drop the price. | Follow @JohnCFierce

@RyanMFierce: ICYMI: Start-Up mag covered the trend of VC investments in clinical trials at major pharmas like Pfizer back in April. More | Follow @RyanMFierce

> Shares of Evotec AG (Frankfurt $EVT) jumped on the news that the Biotechnology Value Fund is investing €30 million in the biotech. Release

> J&J's ($JNJ) Janssen has filed applications in the U.S. and Europe for siltuximab, an experimental therapy designed to treat a rare blood disorder. Report

> Former Dendreon CEO Mitch Gold and analyst David Miller are starting a new biotech hedge fund dubbed Alpine BioVentures. Xconomy reports that the fund will start modestly with "multiple millions." Story

> Fate Therapeutics hopes to sell 4 million shares in its IPO at a range of $14 to $16 each. Report

> Evoke Pharma has set its terms on a proposed $27 million IPO. Story

Medical Device News

@FierceMedDev: Device companies seek legal advice as Chinese corruption crackdown carries on. Item | Follow @FierceMedDev

@MarkHFierce: Medtronic is already rolling out its hospital solutions/consulting business. Diversification proceeds in earnest. Release | Follow @MarkHFierce

@MichaelGFierce: ICYMI: European public health group gets behind tighter device controls. Item | Follow @MichaelGFierce

> Echo Therapeutics' largest shareholder urges rapid reforms. Article

> Taiwan to tackle device industry R&D, training incentives. Story

> Medtronic debuts health services arm. More

Pharma News

@FiercePharma: Executives' TV confessions in China are A) suspect, and B) a disturbing trend. More | Follow @FiercePharma

@EricPFierce: A court-appointed receiver is selling off equipment, patents from failed biosimilars plant. More from FiercePharmaManufacturing | Follow @EricPFierce

@CarlyHFierce: Vivus CEO resigns after one month on the job; former J&J exec Seth H. Z. Fischer appointed. Release | Follow @CarlyHFierce

> GlaxoSmithKline's China unit officially engineered bribery, police say. News

> Novo Nordisk loses big U.S. contracts; Victoza, NovoLog sales to suffer. More

Pharma Manufacturing News

> Cubist recalls four lots of flagship antibiotic. More

> Quality issue keeps Apricus Biosciences from getting Swiss approval for Vitaros. Story

> Receiver selling off equipment, IP from failed biosimilars project. Article

> Hospira recalls product after hair found in one injector. News

> GSK gets interest from buyers for Romania plant. More

> India OKs Wockhardt plant banned by FDA. Report

Biotech Research News

@EmilyMFierce: Former cancer drug could treat diabetes, autoimmune diseases. More | Follow @EmilyMFierce

> Johnson & Johnson forges partnership to fight dengue fever. Article

> High blood pressure therapy speeds TB recovery. News

> Altered gene in mice extends lifespan by 20%. Report

> New opioid pain drug decreases tolerance, side effects. Story

> Worm genome reveals possible drug targets. Item

CRO News

> PPD snags Acurian for recruitment software. News

> CMO Lonza lopping off hundreds of jobs. More

> Duke's CRO nabs another trial deal. Story

> Psi expands in Italy amid global push. Report

> Report: Big CROs soared 10% last year. Article

Biotech IT News

> DNA software startup Desktop Genetics scores £375K in early funding. More

> Report: BGI readies for big genomics IPO. More

> Eagle Genomics captures £590,000 round to feed bioinformatics biz. Article

> AstraZeneca backs web portal for breast cancer docs. Story

> Quantia, provider of software to pharma, lands $10M B round. Item

> Eli Lilly, Humana partner on crunching diabetes data. Article

And Finally… Investigators in London say that a synthetic polymer could be used to prevent the spread of HIV. Release

Suggested Articles

It’s been a minute, but AstraZeneca has gotten the FDA’s all-clear to restart the U.S. study of its COVID-19 vaccine.

Solid Bio is teaming up with Ultragenyx on Duchenne muscular dystrophy in a deal worth $40 million upfront but could net it another $255 million.

The RNAi therapy drove a 72% reduction in urinary oxalate from baseline, boosting Alnylam’s hopes of using the drug in a broad patient population.